Revised forecast
Fiscal year ending March 2027 · Cumulative second quarter and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In China, profit is expected to decline as a result of lower revenue, while solid growth in other regions, contributions from the CN Series in the blood coagulation field, and expansion in emerging markets are expected.
Impairment loss: ¥11,557 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Cumulative second-quarter results 255,000 / Full year 535,000（Cumulative second-quarter results 9.7% / Full year 7.0%） |
| Operating profit | Not disclosed → Cumulative second-quarter results 23,000 / Full year 58,000（Cumulative second-quarter results -30.2% / Full year 11.9%） |
| Profit attributable to owners of the parent | Not disclosed → Cumulative second-quarter results 14,000 / Full year 36,000（Cumulative second-quarter results -26.4% / Full year 1.5%） |
| Net income per share | Not disclosed → Cumulative second-quarter results 22.53 / Full year 57.93 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Cumulative second quarter and full year |
| Previous-period results | Revenue: ¥500,006 million; operating profit: ¥51,831 million; profit before tax: ¥49,051 million; profit for the period attributable to owners of the parent: ¥35,457 million; basic earnings per share: ¥56.89 (fiscal year ended March 2026) |
| Reason for the revision | In China, profit is expected to decline as a result of lower revenue, while solid growth in other regions, contributions from the CN Series in the blood coagulation field, and expansion in emerging markets are expected. |
| Details and amount of extraordinary loss | Impairment loss: ¥11,557 million |
| Dividend forecast revision | For the fiscal year ending March 2027, the company projects an interim dividend of ¥20.00, a year-end dividend of ¥20.00, and an annual dividend of ¥40.00. It is not specified whether this constitutes a revision. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fiscal year ended March 2026, lower sales in Japan and China, a higher cost-of-sales ratio, increased selling, general and administrative expenses, and impairment losses recognized due to changes in the business environment and strategy, among other factors, contributed to the decline in profit. For the fiscal year ending March 2027, profit is expected to decline as a result of lower revenue in China, while solid growth in other regions, contributions from the CN Series in the blood coagulation field, and expansion in emerging markets are expected.